04Mar 2015
MPubmed

At 7 years, the cumulative incidences of new vertebral fractures were significantly lower in the bazedoxifene (6.4%) and bazedoxifene 20 mg (7.6%) groups than in the placebo group (9.9%); the relative risk reductions were 36.5% and 30.4%, respectively (both p < 0.001). Bazedoxifene had no effect on the overall incidence of nonvertebral fractures.

02Feb 2015
MPubmed

As expected, TBS of Naive subjects decreased with age. As expected a TBS preservation has been observed under Alendronate and Risedronate. Testosterone and Calcium and Vitamin D effects on TBS were evaluated for the first time: a similar preservation effect has been observed. A significant TBS increase was observed under Denosumab and PTH. TBS could be a useful tool to monitor treatment effects.

02Feb 2015
MPubmed

Hip fractures continue to increase in absolute numbers, although if the rates are adjusted for age, a downward trend is seen in certain age groups. These findings have various origins, although in the absence of great changes in population structure, we believe that drug treatments for osteoporosis may play a role. There is variability in the change in incidence of hip fractures in different parts of the country.